Scarica l'app Stockscreener
21.78
0.91%
-0.20
Dopo l'orario di chiusura:
21.60
-0.18
-0.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$21.98
Aprire:
$21.75
Volume 24 ore:
6.90M
Relative Volume:
0.88
Capitalizzazione di mercato:
$15.15B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
3.8549
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+0.37%
1M Prestazione:
+3.76%
6M Prestazione:
+100.55%
1 anno Prestazione:
+97.64%
Intervallo 1D:
$21.32
$22.00
Intervallo di 1 settimana:
$20.78
$22.20
Portata 52W:
$8.73
$23.47
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
21.78 | 15.29B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Can Roivant Sciences Ltd. stock double in next 5 yearsMarket Performance Summary & Weekly Stock Breakout Alerts - ulpravda.ru
Is Roivant Sciences Ltd. stock positioned for digital transformation2025 Investor Takeaways & Target Return Focused Stock Picks - ulpravda.ru
How Roivant Sciences Ltd. stock reacts to global recession fears2025 Big Picture & Community Supported Trade Ideas - ulpravda.ru
How Roivant Sciences Ltd. stock performs in rate cut cyclesWeekly Market Outlook & Long Hold Capital Preservation Plans - ulpravda.ru
Aug Big Picture: How Roivant Sciences Ltd. stock reacts to global recession fearsWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
What Roivant Sciences (ROIV)'s Accelerated Brepocitinib Push Means For Shareholders - simplywall.st
A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift - simplywall.st
Why Roivant Sciences Ltd. stock could be next big winner2026 world cup usa national team third place match top scorers high defensive line odds analysis insights - ulpravda.ru
Leerink Partners reiterates Outperform rating on Roivant Sciences stock By Investing.com - Investing.com Australia
Leerink raises price target as Roivant (ROIV) accelerates drug development pipeline - MSN
Penn Davis Mcfarland Inc. Buys 170,456 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Pacer Advisors Inc. Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Psithera spun out of Roivant with $47.5M and immune, inflammatory focus - BioWorld MedTech
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline - Insider Monkey
Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing - MarketScreener
Book value per share of Roivant Sciences Ltd. – DUS:87S - TradingView — Track All Markets
Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2% - MarketBeat
15 Best Stocks Under $25 to Buy Now - Insider Monkey
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock - MarketBeat
Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences Executives Engage in Significant Share Sales - TradingView — Track All Markets
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Insider Confidence In December 2025's Leading Growth Companies - Yahoo! Finance Canada
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates - simplywall.st
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd stock positioned for digital transformationGap Down & High Conviction Trade Alerts - moha.gov.vn
What margin trends mean for Roivant Sciences Ltd. stockFibonacci Extensions & Fast Profit Trading Tips - bollywoodhelpline.com
Ramaswamy-Backed Ambros Launches with $125M - Orange County Business Journal
Roivant Sciences president Sukhatme sells $619k in shares By Investing.com - Investing.com Australia
Roivant Sciences president Sukhatme sells $619k in shares - Investing.com UK
How Investors May Respond To Roivant Sciences (ROIV) Accelerating Brepocitinib Timelines And Patent Litigation - simplywall.st
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock - MSN
Why Roivant Sciences Ltd. stock is in analyst buy zone2025 Fundamental Recap & Reliable Entry Point Trade Alerts - Улправда
US Market Recap: What margin trends mean for Roivant Sciences Ltd stockJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - moha.gov.vn
Sell Signal: Will Roivant Sciences Ltd stock maintain momentum in 2025Weekly Stock Report & Pattern Based Trade Signal System - moha.gov.vn
Can Roivant Sciences Ltd. stock maintain operating marginsJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
How Roivant Sciences Ltd. (87S) stock reacts to fiscal policiesJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 26,831 Shares - MarketBeat
Pres Sukhatme Sells 26,831 ($619.5K) Of Roivant Sciences Ltd [ROIV] - TradingView — Track All Markets
Can Roivant Sciences Ltd. stock outperform in 2025 bull marketMarket Activity Summary & High Conviction Buy Zone Alerts - DonanımHaber
Why Roivant Sciences Ltd. stock remains undervaluedVolume Spike & Consistent Return Strategy Ideas - Bölüm Sonu Canavarı
Will Roivant Sciences Ltd. stock maintain momentum in 2025Weekly Stock Analysis & Long-Term Growth Plans - DonanımHaber
Roivant Sciences Insider Sold Shares Worth $39,065,213, According to a Recent SEC Filing - marketscreener.com
Published on: 2025-12-19 09:31:09 - ulpravda.ru
Will Roivant Sciences Ltd. stock deliver shareholder valueQuarterly Trade Report & Long-Term Safe Return Strategies - Улправда
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 777,332 Shares - MarketBeat
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):